Arrowhead Pharmaceuticals (ARWR) Could Be 3% Undervalued On Late Stage Trial Progress

Arrowhead Pharmaceuticals (ARWR) appears to be 3% undervalued, according to a recent analysis, following positive late-stage trial data for two RNA interference programs. The company's stock has seen significant momentum, with a 7x return over the past year, driven by reassessments of its risk and opportunity mix. While a discounted cash flow model suggests the stock is heavily undervalued, the narrative relies on revenue growth, margin expansion, and successful trial progression, making it sensitive to potential setbacks.